MISSISSIPPIAdopted LEGISLATURECOMMITTEE REGULARAMENDMENT SESSIONNO 20221 By:PROPOSED TO House Bill No.

Representative813 YanceyBY: To:

DrugCommittee PolicyAMEND HOUSEon BILLline NO.35 by deleting the word "Not" and inserting the words "By no" before the word "later".

813AMEND (Asfurther Passedon lines 35 and 36 by deleting the House)words AN"eighteen ACT(18) TOmonths CREATEafter THEthe "MISSISSIPPIeffective STUDYdate ONof THEthis AFFORDABILITYact" OFand INSULINinserting ACT";"December 31, 2022," before the word "submit".

TOAMEND REQUIREfurther THEon STATElines HEALTH36 OFFICERand OF37 THEby MISSISSIPPIdeleting STATEthe DEPARTMENTwords OF"Mississippi HEALTHLegislature" TOand CONDUCTinserting Athe STUDYwords THAT"chairman EXAMINESof CERTAINthe INFORMATIONHouse REGARDINGDrug DIABETESPolicy ANDCommittee SUBMITand TOthe THEchairman CHAIRMENof OFthe BOTHSenate THEDrug HOUSEPolicy ANDCommittee," SENATEafter DRUGthe POLICYword COMMITTEES"the" Aon REPORTline ON36. SUCH STUDY BY NO LATER THAN DECEMBER 31,2022;

22/HR26/HB813A.1J *HR26/HB813A.1J* (MCL/KW) AMEND further the title by deleting the words "MISSISSIPPI LEGISLATURE" on line 5, and inserting "CHAIRMEN OF BOTH THE HOUSE AND FORSENATE RELATEDDRUG PURPOSES.POLICY COMMITTEES" before the word "A".

BEAMEND ITfurther ENACTEDthe BYtitle THEby LEGISLATUREdeleting OFthe THEword STATE"NOT" OFon MISSISSIPPI:line 5, and inserting the words "BY NO" before the word "LATER".

SECTIONAMEND 1.further on line 6 by deleting the words "EIGHTEEN MONTHS AFTER THE EFFECTIVE DATE OF THIS ACT" and inserting "DECEMBER 31, 2022" before the semicolon.

ThisPAGE act26/HB813A.1J shall*HR26/HB813A.1J* be(MCL/KW) known and may be cited as the "Mississippi Study on the Affordability of Insulin Act." SECTION 2.

The State Health Officer of the Mississippi State Department of Health shall:

(a) Conduct a study that examines:

(i) For each type or classification of diabetes, including Type 1 diabetes, Type 2 diabetes, gestational diabetes and other conditions causing reliance on insulin, the effect of the affordability of insulin on:

1.

Adherence to insulin prescriptions;

2.

Rates of diabetic ketoacidosis;

H.

B.

No.

813 *HR43/R1359PH* ~ OFFICIAL ~ G1/2 22/HR43/R1359PH PAGE 1 (MCL\EW) 3.

Downstream impacts of insulin adherence including rates of dialysis treatment and end-stage renal disease;

4.

Spending by state health programs in acute episodes that could have been averted by adhering to an insulin prescription;

and 5.

Other factors, as appropriate, to understand the impacts of insulin affordability on health outcomes and insured and uninsured individuals with diabetes.

(ii) Among the individuals who are unable to afford insulin, the numbers of such individuals:

1.

Who are uninsured;

2.

Who are covered under private health insurance;

and 3.

Who are covered under public health insurance programs;

and (b) By no later than December 31, 2022, submit to the chairman of the House Drug Policy Committee and the chairman of the Senate Drug Policy Committee a report on the Mississippi Study on the Affordability of Insulin.

SECTION 3.

This act shall take effect and be in force from and after July 1, 2022.

H.

B.

No.

813 *HR43/R1359PH* ~ OFFICIAL ~ 22/HR43/R1359PH ST:

Mississippi Study on the Affordability of PAGE 2(MCL\EW) Insulin Act;